Follow-up after COPD exacerbation
A Multicenter Study of the Impact of a COPD Identification and Referral System on Patient Follow Up and Outcomes After an Acute COPD Exacerbation Resulting in an Emergency Department Visit or Hospitalization
Viz.ai, Inc. · NCT07118306
This project will try an AI-enabled workflow tool (Viz COPD) to see if it increases respiratory specialist follow-up and improves outcomes after a COPD flare-up in patients seen in the emergency department.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 485 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | Viz.ai, Inc. (industry) |
| Locations | 2 sites (Cherry Hill, New Jersey and 1 other locations) |
| Trial ID | NCT07118306 on ClinicalTrials.gov |
What this trial studies
This observational study compares patients exposed to an AI-enabled clinical workflow tool (Viz COPD) with a historical control cohort to measure respiratory specialist follow-up and downstream clinical outcomes after an acute COPD exacerbation. The Experimental cohort is collected prospectively with the tool active, the Control cohort is retrospective, and an Exploratory cohort includes both retrospective and prospective data. Primary outcomes include rates and timing of specialist follow-up, rehospitalizations, emergency visits, and mortality within a defined follow-up window. Data are gathered from electronic health records and workflow logs without changing standard clinical treatments.
Who should consider this trial
Good fit: Ideal candidates are adults aged 40 or older with a clinical diagnosis of COPD who present to the emergency department with a moderate or severe exacerbation and who are on dual or triple long-acting bronchodilator inhaler therapy.
Not a fit: Patients unlikely to benefit include those on bronchodilator monotherapy, with tracheostomy, advanced cancer, prior lung transplant, discharged to hospice, those who left against medical advice, or who died during hospitalization.
Why it matters
Potential benefit: If successful, this could increase timely specialist follow-up after COPD exacerbations and reduce readmissions and other adverse outcomes.
How similar studies have performed: Related AI-enabled workflow tools have improved timeliness of specialist notification in acute conditions like stroke, but applying this approach specifically to COPD exacerbation follow-up is relatively novel with limited published evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 40 years or older at the time of arrival to the emergency department. * Patients with a clinical diagnosis of COPD who present to the emergency department for a moderate or severe COPD exacerbation. * A moderate exacerbation is defined as an acute exacerbation requiring either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. * A severe exacerbation is defined as an acute exacerbation requiring hospitalization, or observation for \>24 hours in emergency department/urgent care facility or resulting in death. * Patients on dual (LABA/LAMA, LABA/ICS, LAMA/ICS) or triple (LABA/LAMA/ICS) long-acting bronchodilator inhalers. Exclusion Criteria: * Patients on bronchodilator inhaler monotherapy. * Patients leaving against medical advice or expiring during hospitalization. * Patients with tracheostomy. * Patients with advanced cancer. * Patients who have received a lung transplant. * Discharge to hospice care. * Transfer to another hospital.
Where this trial is running
Cherry Hill, New Jersey and 1 other locations
- Cooper University Health Care — Cherry Hill, New Jersey, United States (RECRUITING)
- Thomas Jefferson University — Philadelphia, Pennsylvania, United States (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: COPD, Chronic obstructive pulmonary disease, Exacerbation, VizCOPD